To investigate this, we divided 139 newly diagnosed pediatric B-ALL patients into two equal groups: the KLF2-low and KLF2-high groups, based on their mRNA expression levels of KLF2, as determined by whole-gene transcriptome sequencing. Here, KLF2 is linked to precursor B-cell acute lymphoblastic leukemia.